BioXcel Therapeutics (BTAI) Return on Sales (2022 - 2026)

BioXcel Therapeutics' Return on Sales history runs 5 years deep, the most recent figure standing at 0.69% for Q1 2026.

• On a quarterly basis, Return on Sales rose 13.0% year-over-year to 0.69% in Q1 2026; TTM through Mar 2026 was 0.98%, a 65.0% decrease from a year earlier, with the FY2025 full-year figure at 1.03%, up 10.0% from the prior year.
• Return on Sales fell to 0.69% in Q1 2026 per BTAI's latest filing, from 0.56% in the prior quarter.
• Across five years, Return on Sales topped out at 0.18% in Q2 2024 and bottomed at 7.13% in Q4 2022.
• The 5-year median for Return on Sales is 0.86% (2024), against an average of 1.75%.
• Across the five-year window, Return on Sales soared 655 bps in 2023 and plunged 147 bps in 2025, its largest moves.
• Year by year, Return on Sales stood at 7.13% in 2022, then soared by 92 bps to 0.59% in 2023, then soared by 66 bps to 0.2% in 2024, then plunged by 183 bps to 0.56% in 2025, then slipped by 23 bps to 0.69% in 2026.
• Per Business Quant, the three latest BTAI Return on Sales figures stand at 0.69% (Q1 2026), 0.56% (Q4 2025), and 1.83% (Q3 2025).